Table 5.
American College of Rheumatology (ACR) criteria scores of 20, 50, and 70 network meta-analysis base case results for combination treatments in DMARD-experienced patients: licensed biologic DMARD combinations versus DMARD alone
| Fixed effect | Random effects | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| OR v DMARD (95% CrI) | % of patients with event (95% CrI) | Probability of best, % | OR v DMARD (95% CrI) | % of patients with event (95% CrI) | Probability of best, % | |
| ACR 20 | ||||||
| DMARD | – | 29.3% (24.9%, 34%) | 0.0% | – | 29.3% (25%, 34%) | 0.0% |
| ABA 10 mg/kg/4 weeks + DMARD | 3.288 (2.597, 4.18)‡ | 57.6% (49.5%, 65.3%) | 0.0% | 3.255 (2.056, 5.159)‡ | 57.4% (44.8%, 69.2%) | 0.0% |
| ADA 40 mg/2 weeks + DMARD | 3.514 (2.65, 4.684)‡ | 59.3% (50.5%, 67.6%) | 0.0% | 3.439 (2.187, 5.303)‡ | 58.7% (46.3%, 69.8%) | 0.0% |
| CZP 200 mg/2 weeks + DMARD | 10.69 (7.383, 15.69)‡ | 81.6% (74.2%, 87.4%) | 70.7% | 11.06 (6.055, 21.06)‡ | 82.1% (70.7%, 90%) | 64.2% |
| ETN 2 × 25 mg/week + DMARD | 8.917 (5.25, 15.53)‡ | 78.7% (67.5%, 87%) | 29.4% | 9.341 (4.845, 19.29)‡ | 79.5% (66%, 89.2%) | 35.1% |
| GOL 50 mg/4 weeks + DMARD | 3.508 (2.18, 5.735)‡ | 59.2% (46.2%, 71.3%) | 0.0% | 3.387 (1.604, 6.863)‡ | 58.4% (39.4%, 74.6%) | 0.2% |
| INF 3 mg/kg/8 weeks + DMARD | 3.364 (2.71, 4.175)‡ | 58.2% (50.5%, 65.4%) | 0.0% | 3.347 (2.271, 4.983)‡ | 58.1% (47.1%, 68.5%) | 0.0% |
| RTX 2 × 1000 mg + DMARD | 3.592 (2.378, 5.47)‡ | 59.8% (48.3%, 70.5%) | 0.0% | 3.716 (1.915, 7.418)‡ | 60.6% (43.5%, 76.1%) | 0.3% |
| TOC 8 mg/kg/4 weeks + DMARD | 4.497 (3.619, 5.61)‡ | 65% (57.8%, 71.7%) | 0.0% | 4.399 (2.704, 7.125)‡ | 64.6% (51.7%, 75.5%) | 0.2% |
| ACR 50 | ||||||
| DMARD | – | 12% (9.4%, 15.1%) | 0.0% | – | 12% (9.4%, 15.1%) | 0.0% |
| ABA 10 mg/kg/4 weeks + DMARD | 3.57 (2.718, 4.727)‡ | 32.7% (24.9%, 41.9%) | 0.0% | 3.633 (2.093, 6.341)‡ | 33.1% (21.1%, 47.8%) | 0.0% |
| ADA 40 mg/2 weeks + DMARD | 3.899 (2.831, 5.446)‡ | 34.7% (25.9%, 44.9%) | 0.0% | 3.87 (2.303, 6.598)‡ | 34.5% (22.6%, 49%) | 0.1% |
| CZP 200 mg/2 weeks + DMARD | 9.013 (5.636, 14.94)‡ | 55.1% (41.7%, 68.5%) | 37.2% | 9.773 (4.604, 22.65)‡ | 57.1% (37.5%, 76.3%) | 37.6% |
| ETN 2 × 25 mg/week + DMARD | 10.22 (5.28, 22.3)‡ | 58.3% (40.5%, 76%) | 61.0% | 11.15 (4.947, 27.95)‡ | 60.4% (39.2%, 79.8%) | 55.6% |
| GOL 50 mg/4 weeks + DMARD | 4.532 (2.521, 8.237)‡ | 38.2% (24.5%, 54.3%) | 0.8% | 4.917 (2.051, 12.34)‡ | 40.1% (21.2%, 63.6%) | 3.6% |
| INF 3 mg/kg/8 weeks + DMARD | 3.538 (2.724, 4.612)‡ | 32.5% (24.9%, 41.2%) | 0.0% | 3.602 (2.246, 5.924)‡ | 32.9% (22.3%, 46.3%) | 0.1% |
| RTX 2 × 1000 mg + DMARD | 3.851 (2.28, 6.819)‡ | 34.3% (22.5%, 49.6%) | 0.2% | 4.103 (1.821, 9.73)‡ | 35.9% (19.2%, 57.8%) | 1.4% |
| TOC 8 mg/kg/4 weeks + DMARD | 5.838 (4.425, 7.773)‡ | 44.3% (35%, 54%) | 0.8% | 5.401 (2.911, 9.561)‡ | 42.3% (27.4%, 58%) | 1.6% |
| ACR 70† | ||||||
| DMARD | – | 4.7% (3.3%, 6.5%) | 0.0% | – | 4.7% (3.4%, 6.5%) | 0.0% |
| ABA 10 mg/kg/4 weeks + DMARD | 3.524 (2.435, 5.213)‡ | 14.7% (9.4%, 22.6%) | 0.0% | 3.954 (1.974, 8.8)‡ | 16.3% (8.2%, 31.6%) | 0.2% |
| ADA 40 mg/2 weeks + DMARD | 3.963 (2.513, 6.5)‡ | 16.3% (9.8%, 26.2%) | 0.0% | 3.868 (1.91, 7.83)‡ | 16% (7.9%, 29.2%) | 0.1% |
| CZP 200 mg/2 weeks + DMARD | 11.43 (5.472, 27.86)‡ | 35.9% (19.8%, 59%) | 25.5% | 13.18 (4.489, 43.5)‡ | 39.2% (17.2%, 69.2%) | 28.5% |
| ETN 2 × 25 mg/week + DMARD | 18.99 (5.098, 130.6)‡ | 48.3% (19.4%, 86.6%) | 69.5% | 20.69 (4.921, 158.6)‡ | 50.6% (18.8%, 89%) | 64.7% |
| GOL 50 mg/4 weeks + DMARD | 4.73 (2.069, 12.2)‡ | 18.9% (8.6%, 39%) | 1.3% | 4.988 (1.401, 18.28)‡ | 19.6% (6.2%, 48.4%) | 2.7% |
| INF 3 mg/kg/8 weeks + DMARD | 3.549 (2.479, 5.133)‡ | 14.8% (9.5%, 22.4%) | 0.0% | 3.694 (2.021, 7.307)‡ | 15.4% (8.3%, 28%) | 0.1% |
| RTX 2 × 1000 mg + DMARD | 2.399 (1.168, 5.272)‡ | 10.6% (5%, 21.8%) | 0.0% | 2.644 (0.909, 8.387) | 11.5% (4%, 30%) | 0.2% |
| TOC 8 mg/kg/4 weeks + DMARD | 7.991 (5.211, 12.79)‡ | 28.2% (18.4%, 41.2%) | 3.7% | 7.656 (3.442, 16.5)‡ | 27.2% (13.7%, 46.6%) | 3.6% |
Notes:
†
ACR 70 data with continuity correction;
‡
licensed combination had significantly higher odds (based on the 95% CrI) compared to DMARD.
Abbreviations: ABA, abatacept; ADA, adalimumab; ANA, anakinra; CrI, credible interval (Bayesian probability interval); CZP, certolizumab pegol; DMARD, disease-modifying antirheumatic drug (MTX or SUL); ETN, etanercept; exp, experienced; GOL, golimumab; INF, infliximab; MTX, methotrexate; OR, odds ratio; RTX, rituximab; SUL, sulfasalazine; TOC, tocilizumab.